BOSTON, Nov. 6, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that its Board of Directors has authorized the repurchase of up to $2 billion worth of PTC common stock through September 30, ...
It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have added about 2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading ...
PTC Therapeutics signed a $1billion upfront deal with Novartis for its Huntington's program, with potential milestones of $1.9 billion. Interim Phase 2 data shows PTC518 reduces mutant protein levels ...
PTC stock is recommended as a buy due to its exposure to key growth verticals and long-term growth outlook. PTC provides software solutions for industries heavy in design, manufacturing, and project ...
Vuforia Mixed Reality Solutions Enable Improved Workforce Efficiency and Training with Out-of-the Box Support for Microsoft HoloLens 2 BARCELONA, Spain--(BUSINESS WIRE)--PTC (NASDAQ: PTC) today ...
PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Novartis will partner with PTC Therapeutics to expand the use of PTC’s small molecule splicing platform to develop PTC’s PTC518 Huntington’s disease program and an unspecified number of related ...
It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results